Skip to main content
. Author manuscript; available in PMC: 2022 Mar 11.
Published in final edited form as: J Med Chem. 2021 Feb 12;64(5):2691–2704. doi: 10.1021/acs.jmedchem.0c01922

Figure 6:

Figure 6:

TO-317 shows superior HDAC6 selectivity and potency in MV4–11 and MM.1S cells. (A) MV4–11 cells treated with increasing doses (0.25 μM - 1 μM) of Citarinostat and TO-317 show accumulation of Ac-α-tubulin for TO-317 at 0.25 μM but not for Citarinostat. (B) Similar dose-dependent responses were observed for both inhibitors in MM.1S cells.